Patents by Inventor David G. Roe
David G. Roe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11807629Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: July 1, 2021Date of Patent: November 7, 2023Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Patent number: 11753401Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: April 5, 2023Date of Patent: September 12, 2023Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Patent number: 11746102Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: April 7, 2023Date of Patent: September 5, 2023Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20230242516Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: ApplicationFiled: April 5, 2023Publication date: August 3, 2023Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20230242517Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: ApplicationFiled: April 7, 2023Publication date: August 3, 2023Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20220242832Abstract: The present invention provides an improved process for preparation of the (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid (referred to as compound of the structural formula (III)), which is a useful key intermediate for the synthesis of Selinexor ((Z)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide). The process comprises reaction of the compound of the structural formula (I) (as described herein) with the compound of the structural formula (II) (as described herein) in the presence of a catalyst, an organic base and an ether-containing solvent. The subsequent hydrolysis of the formed compound of the structural formula (IIIa) (as described herein) is performed without isolation of the compound of the structural formula (IIIa), providing compound of the structural formula (III) in high yield and stereoselectivity.Type: ApplicationFiled: May 1, 2020Publication date: August 4, 2022Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20220135545Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: ApplicationFiled: July 1, 2021Publication date: May 5, 2022Inventors: Brian C. Austad, David G. Roe
-
Patent number: 11078220Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: GrantFiled: May 1, 2020Date of Patent: August 3, 2021Assignee: Mallinckrodt Hospital Products IP LimitedInventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
-
Patent number: 11078190Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: November 11, 2019Date of Patent: August 3, 2021Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20200283419Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: ApplicationFiled: November 11, 2019Publication date: September 10, 2020Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20200255458Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: ApplicationFiled: May 1, 2020Publication date: August 13, 2020Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
-
Patent number: 10662209Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: GrantFiled: March 11, 2019Date of Patent: May 26, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
-
Patent number: 10519139Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: August 14, 2015Date of Patent: December 31, 2019Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20190202846Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: ApplicationFiled: March 11, 2019Publication date: July 4, 2019Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
-
Patent number: 10273255Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: GrantFiled: January 11, 2018Date of Patent: April 30, 2019Assignee: INFACARE PHARMACEUTICAL CORPORATIONInventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
-
Publication number: 20180215733Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: ApplicationFiled: August 14, 2015Publication date: August 2, 2018Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20180134735Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: ApplicationFiled: January 11, 2018Publication date: May 17, 2018Inventors: George S. DRUMMOND, Robert CAROSELLI, Keith A. COOKE, Daniel LEVIN, David G. ROE, Christopher P. BOUCHER
-
Patent number: 9902745Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: GrantFiled: November 4, 2016Date of Patent: February 27, 2018Assignee: INFACARE PHARMACEUTICAL CORPORATIONInventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
-
Publication number: 20170073362Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: ApplicationFiled: November 4, 2016Publication date: March 16, 2017Inventors: George S. DRUMMOND, Robert CAROSELLI, Keith A. COOKE, Daniel LEVIN, David G. ROE, Christopher P. BOUCHER
-
Patent number: 9517239Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: GrantFiled: July 8, 2015Date of Patent: December 13, 2016Assignee: Infacare Pharmaceutical CorporationInventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher